Prostaglandin E, has been reported both to stimulate glycogen-phosphorylase activity (glycogenolytic effect) and to inhibit the glucagon-stimulated glycogen-phosphorylase activity (antiglycogenolytic effect) in rat hepatocytes. It was the purpose of this study to resolve this apparent contradiction and to characterize the signalling pathways and receptor subtypes involved in the opposing prostaglandin E, actions.Prostaglandin E, (10 pM) increased glucose output, glycogen-phosphorylase activity and inositol trisphosphate formation in hepatocyte cell culture andor suspension. In the same systems, prostaglandin E, decreased the glucagon-stimulated (1 nM) glycogen-phosphorylase activity and cAMP formation.The signalling pathway leading to the glycogenolytic effect of PGE, was interrupted by incubation of the hepatocytes with 4P-phorbol 12-myristate 13-acetate (100 nM) for 10 min, while the antiglycogenolytic effect of prostaglandin E, was not attenuated.The signalling pathway leading to the antiglycogenolytic effect of prostaglandin E, was interrupted by an incubation of cultured hepatocytes with pertussis toxin (100 ng/ml) for 18 h, whereas the glycogenolytic effect of prostaglandin E, was enhanced.The EP,/EP, prostaglandin-E,-receptor-specific prostaglandin E, analogue Sulproston had a stronger glycogenolytic potency than the EP, prostaglandin-E,-receptor-specific prostaglandin E, analogue Misoprostol. The antiglycogenolytic potency of both agonists was equal.It is concluded that the glycogenolytic and the antiglycogenolytic effects of prostaglandin E, are mediated via different signalling pathways in hepatocytes possibly involving EP, and EP, prostaglandin E, receptors, respectively.Prostaglandins have been implicated to participate in cell to cell signal propagation between non-parenchymal and parenchymal cells in the liver. They are synthesized only in non-parenchymal liver cells [ 11, primarily Kupffer cells, but also in endothelial cells and Ito cells. They are degraded mainly by the parenchymal cells, i.e. hepatocytes [2-61, which also have been shown to possess binding sites for prostaglandins [2,[7][8][9][10]. The role of prostaglandins in the regulation of liver metabolism has been discussed controversially in previous studies. The use of cyclooxygenase inhibitors have revealed the involvement of prostaglandins in signalling pathways leading to an increase in glycogenolysis and glucose output elicited by such diverse stimuli as zymoCorrespondence to G. P.